Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.
Exact Sciences to participate in May 2023 investor conference Read More »
Rockwell Medical, Inc. announced that the Company expanded its geographic footprint by entering a long-term supply agreement with Global Medical Supply Chain LLC to begin selling Rockwell’s hemodialysis concentrates products into the United Arab Emirates.
Rockwell Medical Announces Global Expansion into the United Arab Emirates Read More »
In today’s job market, health and retirement benefits are vital tools for competing for employees. The latest tool? Fertility benefits.
Are fertility benefits becoming the latest work perk? Read More »
Learn the considerations product leaders must evaluate as they develop solutions to ease clinician burnout and deliver fast ROI.
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its participation in the annual Digestive Disease Week conference being held this year May 6-9 in Chicago, IL.
Mainz Biomed to Participate in Digestive Disease Week 2023 Read More »
Astellas Pharma Inc. and Iveric bio, Inc. announced that on April 29, 2023, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash
Astellas Enters into Definitive Agreement to Acquire Iveric Bio Read More »
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy and cetrelimab monotherapy in patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy.
As a next step in focusing on the US market The Board of Directors of Immunovia AB, has decided to appoint Jeff Borcherding, until now President of Immunovia’s US operation, as global CEO.
UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL.
